FDA ODAC Recommends CARVYKTI (ciltacabtagene autoleucel) for Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-odac-recommends-carvykti-cilta-cell-earlier-treatment-relapse-refractory-myeloma)